Against the backdrop of the continuous expansion of the global pharmaceutical trade scale, cross-border pharmaceutical circulation is moving from "achievable" to "emphasizing both high efficiency and strong compliance". According to public industry data, the global pharmaceutical logistics market is expected to maintain a compound annual growth rate of 6%–8% by 2030, with the proportion of cold chain pharmaceuticals continuing to rise. This also means that enterprises are facing higher standard challenges in the transportation, customs declaration and clearance links.

In this context, platforms with comprehensive capabilities like Dengyue Pharmaceutical are helping customers improve customs clearance efficiency and supply chain stability through systematic services.

I. From "Transportation" to "Supply Chain": The Upgrade Logic of Pharmaceutical Logistics

Pharmaceuticals are different from ordinary commodities. Their transportation process must meet the regulatory requirements such as GSP and GDP, especially in the following aspects which have more stringent requirements:

● Temperature control (2–8°C, 15–25°C and other intervals)

● Stable timeliness (avoid chain breakage or delay)

● Traceability (full-process records)

● Packaging safety (shockproof, anti-pollution)

Based on these needs, Dengyue Pharmaceutical's services have built a multi-level transportation network by integrating air main lines, regional transshipment and terminal distribution resources, achieving:

● Customized transportation route design (covering mainstream markets such as Asia, Europe and the Middle East)

● Specialized solutions for cold chain products (suitable for vaccines, monoclonal antibodies, cell therapy products)

● Visual logistics system (real-time monitoring of transportation status)

This model, which upgrades from "single transportation" to "overall supply chain management", has significantly improved the certainty of pharmaceutical delivery.

II. Customs Declaration Link: The Core Node Determining Customs Clearance Efficiency

In the pharmaceutical export process, customs declaration is not only an administrative link, but also a concentration point of compliance risks. According to public data from China Customs, the proportion of delays caused by incorrect declarations or incomplete documents exceeds 20%.

To address this pain point, Dengyue Pharmaceutical's services have established a standardized customs declaration support system:

1. Pre-compliance Review

● Verification of pharmaceutical registration certificates/approvals

● Matching of export qualifications (MAH, operation license, etc.)

● Document consistency verification

2. Accurate Declaration Management

● Standard classification of HS codes (reducing the probability of inspection)

● Standardized filling of customs declaration elements

● Docking with electronic declaration systems

3. Policy Dynamic Response

● Real-time tracking of NMPA and drug regulatory policies of various countries

● Formulating differentiated strategies for special drugs (anti-tumor drugs, orphan drugs)

Through the operation of a professional team, it can effectively avoid problems such as order rejection and customs detention, and improve the one-time release rate.

III. Customs Clearance Efficiency: The Key Variable Affecting Delivery Cycle

In the importing country or region, customs clearance efficiency directly determines whether pharmaceuticals can enter the terminal market on time. Especially in Southeast Asia, the Middle East and Latin American markets, there are great differences in regulations among different countries.

The customs clearance services supporting Dengyue Pharmaceutical's products focus on solving the following difficulties:

● Coordinated handling of import licenses

● Pre-evaluation of tax structure (tariff + value-added tax)

● Adaptation to local regulations (labeling, language, packaging requirements)

● Abnormal handling mechanism (inspection, supplementary documents, policy adjustments)

In addition, through the pre-clearance mechanism, the customs clearance time can be shortened to 1–3 working days (depending on the country), greatly reducing the cost of port detention.

IV. One-Stop Supply Chain Integration: Improving Overall Operational Efficiency

Currently, China's pharmaceutical cross-border e-commerce industry is expanding at a compound annual growth rate of 18.7%, and the market scale is expected to exceed 130 billion yuan by 2030. The efficiency and compliance of pharmaceutical exports have become the core competitiveness of enterprises.

Based on industry needs, Dengyue Pharmaceutical integrates full-process services such as compliance consulting, intelligent logistics, standardized customs declaration and professional customs clearance, builds a one-stop solution covering the entire pharmaceutical export chain, seamlessly connects various services and products of Dengyue Pharmaceutical, and forms a closed-loop service model of "compliance + logistics + customs clearance".

With the tightening of global regulations (such as EU GDP standards and US FDA import requirements), cross-border pharmaceutical circulation will show the following trends:

● The proportion of cold chain will continue to rise

● Compliance thresholds will be further raised

● Digital supply chains will become the standard

● Demand for integrated services will grow

In this trend, platforms with logistics integration capabilities and international compliance experience will become key supporting forces in the industry.

Conclusion

Pharmaceutical export is no longer just a "transportation issue", but a systematic project covering compliance, efficiency and risk control. By integrating logistics, customs declaration and clearance resources, Dengyue Pharmaceutical's products and services are helping enterprises build a more stable and efficient cross-border pharmaceutical supply chain system.

For pharmaceutical enterprises hoping to expand the international market, choosing a professional service platform will directly determine their global delivery capacity and market response speed.